Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The molecule "novel transcript, antisense to CRCP" (ENSG00000290090) represents a long non-coding RNA transcribed from the DNA strand opposite to the CRCP gene. Natural antisense transcripts (NATs) like this often regulate the expression of their corresponding sense gene through a variety of mechanisms, including chromatin modification, influencing sense transcript stability, and transcriptional interference[1][3][6]. While these antisense RNAs can be essential modulators of molecular and cellular processes, there is currently no evidence to suggest that this specific transcript itself is a therapeutic target, a member of major druggable protein families, or that it directly interacts with any drugs as of the present data.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural antisense transcript to CRCP.